共 50 条
- [41] Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemiaFRONTIERS IN PEDIATRICS, 2022, 10Kim, YeojaeKim, SeongkooLee, Jong MiAhn, AriYoo, Jae WonLee, Jae WookCho, BinChung, Nack-GyunKim, YonggooKim, Myungshin
- [42] BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on SurvivalCANCER INVESTIGATION, 2015, 33 (09) : 451 - 458Barbosa Pagnano, Katia BorgiaBendit, IsraelBoquimpani, CarlaDe Souza, Carmino AntonioMiranda, Eliana C. M.Zalcberg, IlanaLarripa, IreneNardinelli, LucianaSilveira, Rosana AntunesFogliatto, LauraSpector, NelsonFunke, VaneuzaPasquini, RicardoHungria, VaniaChiattone, Carlos SergioClementino, NelmaConchon, MonikaBeatriz Moiraghi, ElenaLopez, Jose LuisPavlovsky, CarolinaPavlovsky, Miguel A.Cervera, Eduardo E.Antonio Meillon, LuisSimoes, BelindaHamerschlak, NelsonMagarinos Bozzano, Alicia HelenaMayta, ErnestoCortes, JorgeBengio, Raquel M.
- [43] Prognostic Significance of Transcript-Type BCR-ABL1 in Chronic Myeloid LeukemiaMEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2020, 12Molica, MatteoAbruzzese, ElisabettaBreccia, Massimo
- [44] OUTCOMES OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH 10%≤AND>10% BCR-ABL1 (IS) TRANSCRIPT LEVELS AFTER 3 MONTHS OF GENERIC IMATINIB TREATMENTHAEMATOLOGICA, 2015, 100 : 439 - 440Baslar, Z.Eskazan, A. E.Ayer, M.Kantarcioglu, B.Demirel, N.Aydin, D.Aydinli, F.Yokus, O.Sadri, S.Erdogan, I.Berk, S.Yalniz, F. F.Elverdi, T.Salihoglu, A.Ar, M. C.Aydin, S. OngorenAydin, Y.Tuzuner, N.Ozbek, U.Soysal, T.
- [45] Clinicopathological Variables and Outcome in Chronic Phase Chronic Myeloid Leukemia Associated with BCR-ABL1 Transcript Type and ObesityBLOOD, 2020, 136Abdulla, Mohammad Abdul-JaberChandra, PremEl Akiki, SusanaSorio, ClaudioTomasello, LuisaBoni, ChristianYassin, Mohamed A.
- [46] Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitorsCANCER MEDICINE, 2019, 8 (11): : 5173 - 5182Etienne, GabrielDulucq, StephanieHuguet, FrancoiseSchmitt, AnnaLascaux, AxelleHayette, SandrineFort, Marie-PierreSujobert, PierreBijou, FontanetMorisset, StephaneTavitian, SuzanneBidet, AudreyTurcq, BeatriceRobbesyn, FannyChollet, ClaudineBelloc, FrancisDurrieu, FrancoiseMahon, Francois-XavierNicolini, Franck E.
- [47] Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid LeukemiaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S120 - S128Soverini, Simonade Benedittis, CaterinaMancini, ManuelaMartinelli, Giovanni
- [48] BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single InstitutionACTA HAEMATOLOGICA, 2015, 134 (04) : 248 - 254Ribeiro, Beatriz FelicioVergilio, Bruna RochaMartins Miranda, Eliana CristinaAlmeida, Maria HelenaDelamain, Marcia Torresanda Silveira, Rosana Antunesde Souza, Carmino AntonioAlbuquerque, Dulcineia MartinsDos Santos, AndreyDuarte, Vagner OliveiraOliveira-Duarte, Gislaine BorbaLorand-Metze, IreneBarbosa Pagnano, Katia Borgia
- [49] THE IMPACT OF DIFFERENT BCR-ABL1 TRANSCRIPT ON OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS: A MONOCENTRIC REAL LIFE EXPERIENCEHAEMATOLOGICA, 2017, 102 : 21 - +Farina, M.D'adda, M.Schieppati, F.Cerqui, E.Rossi, G.
- [50] STUDY OF MUTATIONS IN THE KINASE DOMAIN OF BCR-ABL1 BY NGS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIAHAEMATOLOGICA, 2020, 105 : 239 - 239Stuckey, RuthFlorido, Ortega YaniraRodriguez, Lopez Juan FranciscoBilbao, Sieyro CristinaGomez, Casares Maria Teresa